Literature DB >> 19578981

High expression of claudin-1 protein in papillary thyroid tumor and its regional lymph node metastasis.

Júlia Németh1, Zsuzsanna Németh, Péter Tátrai, Ilona Péter, Aron Somorácz, Attila Marcell Szász, András Kiss, Zsuzsa Schaff.   

Abstract

Claudins, known as major contributors in the formation of the tight junction, are differentially expressed in malignant tumors as compared to the corresponding healthy tissues. Therefore, they are thought to play a role in carcinogenesis and tumor progression. Altered expression of claudin-1 has been reported in several tumor types including endometrial, papillary renal cell and colonic carcinoma, and increased claudin-1 mRNA levels have been observed in papillary thyroid carcinoma (PTC). In this study, we aimed at determining the pattern of claudin-1 expression in various types of thyroid lesions at the protein level and investigating the immunolocalization of beta-catenin reported to regulate claudin-1 expression. Samples included 19 PTCs, ten cases of corresponding regional lymph node metastasis, eight papillary microcarcinomas (PMC), 17 follicular thyroid carcinomas (FTC) and 19 follicular adenomas (FA). All cases were evaluated by quantitative immunohistochemistry. Conspicuous claudin-1 immunostaining was detected in the majority of PTC/PMC primary tumors and lymph node metastases (19/27 and 9/10, respectively). On the other hand, we found weak or no claudin-1 expression in any of the FA and FTC cases or peritumoral non-malignant thyroid tissues. Our data prove that high claudin-1 protein expression is specific for PTC and its regional lymph node metastases, while we failed to verify that claudin-1 is regulated by beta-catenin in thyroid tumors. Based on these results, claudin-1 may be a useful tumor marker for PTC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19578981     DOI: 10.1007/s12253-009-9182-9

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  36 in total

Review 1.  Tight junction proteins.

Authors:  L González-Mariscal; A Betanzos; P Nava; B E Jaramillo
Journal:  Prog Biophys Mol Biol       Date:  2003-01       Impact factor: 3.667

2.  Pathologic features of Hashimoto's-associated papillary thyroid carcinomas.

Authors:  M Di Pasquale; J L Rothstein; J P Palazzo
Journal:  Hum Pathol       Date:  2001-01       Impact factor: 3.466

3.  Increased expression of claudins in cervical squamous intraepithelial neoplasia and invasive carcinoma.

Authors:  Gábor Sobel; Csilla Páska; István Szabó; András Kiss; Anna Kádár; Zsuzsa Schaff
Journal:  Hum Pathol       Date:  2005-02       Impact factor: 3.466

4.  Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma.

Authors:  Ying Y Liu; Hans Morreau; Job Kievit; Johannes A Romijn; Nancy Carrasco; Johannes W Smit
Journal:  Eur J Endocrinol       Date:  2008-03       Impact factor: 6.664

5.  Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma.

Authors:  Yu-Chih Chao; Szu-Hua Pan; Shuenn-Chen Yang; Sung-Liang Yu; Ting-Fang Che; Chung-Wu Lin; Mu-Shiun Tsai; Gee-Chen Chang; Che-Hsiang Wu; Yi-Ying Wu; Yung-Chie Lee; Tse-Ming Hong; Pan-Chyr Yang
Journal:  Am J Respir Crit Care Med       Date:  2008-09-11       Impact factor: 21.405

6.  Tight junctions in thyroid carcinogenesis: diverse expression of claudin-1, claudin-4, claudin-7 and occludin in thyroid neoplasms.

Authors:  Vassiliki N Tzelepi; Athanassios C Tsamandas; Helen D Vlotinou; Constantine E Vagianos; Chrisoula D Scopa
Journal:  Mod Pathol       Date:  2007-10-26       Impact factor: 7.842

7.  Claudin-1 expression is induced by tumor necrosis factor-alpha in human pancreatic cancer cells.

Authors:  Jun Kondo; Fuyuki Sato; Tomomi Kusumi; Yang Liu; Ohashi Motonari; Tatsusuke Sato; Hiroshi Kijima
Journal:  Int J Mol Med       Date:  2008-11       Impact factor: 4.101

8.  Expression transformation of claudin-1 in the process of gastric adenocarcinoma invasion.

Authors:  Yong-Lian Wu; Sheng Zhang; Guo-Rong Wang; Yu-Peng Chen
Journal:  World J Gastroenterol       Date:  2008-08-21       Impact factor: 5.742

9.  Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin.

Authors:  M Furuse; K Fujita; T Hiiragi; K Fujimoto; S Tsukita
Journal:  J Cell Biol       Date:  1998-06-29       Impact factor: 10.539

10.  Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study.

Authors:  Anna-Mária Tokés; Janina Kulka; Sándor Paku; Agnes Szik; Csilla Páska; Pál Kaposi Novák; László Szilák; András Kiss; Krisztina Bögi; Zsuzsa Schaff
Journal:  Breast Cancer Res       Date:  2005-01-31       Impact factor: 6.466

View more
  12 in total

Review 1.  Epithelial cell polarity and tumorigenesis: new perspectives for cancer detection and treatment.

Authors:  Danila Coradini; Claudia Casarsa; Saro Oriana
Journal:  Acta Pharmacol Sin       Date:  2011-04-18       Impact factor: 6.150

2.  Expression of papillary thyroid carcinoma-associated molecular markers and their significance in follicular epithelial dysplasia with papillary thyroid carcinoma-like nuclear alterations in Hashimoto's thyroiditis.

Authors:  Heng Ma; Jin Yan; Chao Zhang; Shenghui Qin; Lingzhi Qin; Liwei Liu; Xi Wang; Naping Li
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

3.  The Value of HBME-1 and Claudin-1 Expression Profile in the Distinction of BRAF-Like and RAS-Like Phenotypes in Papillary Thyroid Carcinoma.

Authors:  Hasan Gucer; Pelin Bagci; Recep Bedir; Ibrahim Sehitoglu; Ozgur Mete
Journal:  Endocr Pathol       Date:  2016-09       Impact factor: 3.943

4.  Expression of claudin 1, 4 and 7 in thyroid neoplasms.

Authors:  Dinç Süren; Mustafa Yildirim; Alper Sayiner; Arsenal Sezgin Alikanoğlu; Irem Atalay; Umut Riza Gündüz; Vildan Kaya; Şeyda Gündüz; Mehmet Tahir Oruç; Cem Sezer
Journal:  Oncol Lett       Date:  2017-03-27       Impact factor: 2.967

5.  Claudin 1 in breast tumorigenesis: revelation of a possible novel "claudin high" subset of breast cancers.

Authors:  Yvonne Myal; Etienne Leygue; Anne A Blanchard
Journal:  J Biomed Biotechnol       Date:  2010-05-13

6.  Identification of Claudin 1 Transcript Variants in Human Invasive Breast Cancer.

Authors:  Anne A Blanchard; Teresa Zelinski; Jiuyong Xie; Steven Cooper; Carla Penner; Etienne Leygue; Yvonne Myal
Journal:  PLoS One       Date:  2016-09-20       Impact factor: 3.240

7.  Increase in Toxicity of Anticancer Drugs by PMTPV, a Claudin-1-Binding Peptide, Mediated via Down-Regulation of Claudin-1 in Human Lung Adenocarcinoma A549 Cells.

Authors:  Haruka Nasako; Yui Takashina; Hiroaki Eguchi; Ayaka Ito; Yoshinobu Ishikawa; Toshiyuki Matsunaga; Satoshi Endo; Akira Ikari
Journal:  Int J Mol Sci       Date:  2020-08-17       Impact factor: 5.923

8.  Analysis of the distribution and expression of some tumor invasiveness markers in palate squamous cell carcinomas.

Authors:  Adrian Pătru; Valeriu Şurlin; Claudiu Mărgăritescu; Eduard Mihai Ciucă; Marius Matei; Mircea Sebastian Şerbănescu; Adrian Camen
Journal:  Rom J Morphol Embryol       Date:  2020 Oct-Dec       Impact factor: 0.833

Review 9.  Claudin-1, A Double-Edged Sword in Cancer.

Authors:  Ajaz A Bhat; Najeeb Syed; Lubna Therachiyil; Sabah Nisar; Sheema Hashem; Muzafar A Macha; Santosh K Yadav; Roopesh Krishnankutty; Shanmugakonar Muralitharan; Hamda Al-Naemi; Puneet Bagga; Ravinder Reddy; Punita Dhawan; Anthony Akobeng; Shahab Uddin; Michael P Frenneaux; Wael El-Rifai; Mohammad Haris
Journal:  Int J Mol Sci       Date:  2020-01-15       Impact factor: 5.923

10.  Targeting claudin-overexpressing thyroid and lung cancer by modified Clostridium perfringens enterotoxin.

Authors:  Anna Piontek; Miriam Eichner; Denise Zwanziger; Laura-Sophie Beier; Jonas Protze; Wolfgang Walther; Sarah Theurer; Kurt Werner Schmid; Dagmar Führer-Sakel; Jörg Piontek; Gerd Krause
Journal:  Mol Oncol       Date:  2020-01-08       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.